Tesaglitazar
Tesaglitazar is a proposed treatment for type 2 diabetes.[1]
The drug had completed several phase III clinical trials,[2] however in May, 2006 AstraZeneca announced that it had discontinued further development.[3]
References
- ↑ Wilding JP, Gause-Nilsson I, Persson A (2007). “Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes”. Diab Vasc Dis Res. 4 (3): 194–203. doi:10.3132/dvdr.2007.040. PMID 17907109.
- ↑ “GALIDA™ (tesaglitazar) Clinical Trial Report Summaries”. AstraZeneca. Retrieved 2008-03-17.
- ↑ “AstraZeneca Discontinues Development of GALIDA (tesaglitazar)”. AstraZeneca. 2006-05-04. Retrieved 2008-03-17.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH